European Society for Medical Oncology (ESMO) shared a post on LinkedIn:
“Disappointing results from neoadjuvant and adjuvant immunotherapy Clinical Trials in head and neck squamous cell cancer (HNSCC) may be related to tumour heterogeneity. While it is often considered a single disease, HPV-positive and HPV-negative head and neck cancers are distinct malignancies that respond differently to immunotherapy.
Sandra Schmitz considers how researchers can learn from disease biology to improve trial design, including enrolment of homogenous patient populations, such as HPV-negative disease only or by specific PD-L1 status.
Read her Opinion piece in the ESMO Daily Reporter.”
More from ESMO25.